Browsing Tag
Paul Hastings
2 posts
Chemomab Therapeutics (CMMB) and Scipher Medicine to merge in $150m reverse deal
Scipher Medicine and Chemomab are merging in all-stock deal, taking Scipher public via reverse merger. $30M PIPE led by Northpond. Q4 2026 close, H1 2028 Phase 2 data.
Ligand Pharmaceuticals (LGND) to acquire XOMA Royalty (XOMA) for $739m as biotech royalty consolidation accelerates
Ligand is buying XOMA for $739 million in cash. The real story sits inside a CVR tied to a $19.7 billion Johnson and Johnson royalty fight.